| Nome |
# |
|
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs, file e31e124b-f9cb-987f-e053-3705fe0a095a
|
536
|
|
Current and Future Chemotherapy for Chagas Disease, file e31e124b-f788-987f-e053-3705fe0a095a
|
336
|
|
The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant, file e31e124d-c1a2-987f-e053-3705fe0a095a
|
285
|
|
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To InhibitTrypanosoma bruceiPteridine Reductase in Support of Early-Stage Drug Discovery, file e31e124d-29e1-987f-e053-3705fe0a095a
|
207
|
|
New chromane-based derivatives as inhibitors of mycobacterium tuberculosis salicylate synthase (mbti): Preliminary biological evaluation and molecular modeling studies, file e31e124d-6c1c-987f-e053-3705fe0a095a
|
144
|
|
New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents, file e31e124f-0de9-987f-e053-3705fe0a095a
|
144
|
|
In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?, file e31e124e-5559-987f-e053-3705fe0a095a
|
123
|
|
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent, file e31e124d-a229-987f-e053-3705fe0a095a
|
62
|
|
Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy, file e31e1250-7e8c-987f-e053-3705fe0a095a
|
59
|
|
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections, file e31e1250-0d79-987f-e053-3705fe0a095a
|
42
|
|
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections, file e31e1250-6145-987f-e053-3705fe0a095a
|
36
|
|
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds, file e31e1250-3ee5-987f-e053-3705fe0a095a
|
27
|
|
Privileged structures as leads in medicinal chemistry, file e31e124a-9702-987f-e053-3705fe0a095a
|
24
|
|
Compounds having antiparasitic activity, file e31e124d-efcc-987f-e053-3705fe0a095a
|
19
|
|
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth, file a2cae1de-bd1b-426b-91e9-1b996303dd0b
|
15
|
|
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth, file aa21c5db-c206-459d-83d7-a5a0a3c06e02
|
13
|
|
Oxidative Modification of Aldose Reductase Induced By Copper Ion. Definition Of The Metal-Protein Interaction Mechanism, file e31e124b-e28d-987f-e053-3705fe0a095a
|
9
|
|
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics, file e31e124d-ca30-987f-e053-3705fe0a095a
|
6
|
|
Iron acquisition pathways as targets for antitubercular drugs, file e31e124f-dacb-987f-e053-3705fe0a095a
|
5
|
|
Interaction of nanoparticles with immunocompetent cells: nanosafety considerations., file d8864aa6-f7b4-45b5-8d1b-1a39c0752896
|
4
|
|
Synthesis and structure-activity relationships of 1-aralkyl-4- benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent σ ligands, file e31e124a-9d7d-987f-e053-3705fe0a095a
|
4
|
|
Colloidal systems for CNS drug delivery, file e31e124a-a126-987f-e053-3705fe0a095a
|
4
|
|
Is there a clinical future for polymeric nanoparticles as brain targeting drug delivery agents?, file e31e124a-a337-987f-e053-3705fe0a095a
|
4
|
|
Designed multiple ligands: basic research vs clinical outcomes, file e31e124a-a338-987f-e053-3705fe0a095a
|
4
|
|
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds, file e31e124d-29f9-987f-e053-3705fe0a095a
|
4
|
|
Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution, file e31e124a-9da6-987f-e053-3705fe0a095a
|
3
|
|
ANTICANCER DRUGS, file e31e124d-a391-987f-e053-3705fe0a095a
|
3
|
|
Targeting the Central Nervous System: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123, file e31e124a-99cb-987f-e053-3705fe0a095a
|
2
|
|
Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures, file e31e124a-9e25-987f-e053-3705fe0a095a
|
2
|
|
STAT3 as Target for cancer drug discovery, file e31e124a-9fc9-987f-e053-3705fe0a095a
|
2
|
|
Challenges in the design of clinically useful brain-targeted drug nanocarriers, file e31e124a-a8dd-987f-e053-3705fe0a095a
|
2
|
|
Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy, file e31e124c-bf81-987f-e053-3705fe0a095a
|
2
|
|
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections, file e31e124d-25ba-987f-e053-3705fe0a095a
|
2
|
|
Iron acquisition pathways as targets for antitubercular drugs, file e31e124d-7216-987f-e053-3705fe0a095a
|
2
|
|
Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase, file e31e124a-955e-987f-e053-3705fe0a095a
|
1
|
|
Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives, file e31e124a-96ac-987f-e053-3705fe0a095a
|
1
|
|
Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles, file e31e124a-9e89-987f-e053-3705fe0a095a
|
1
|
|
Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier, file e31e124a-9ece-987f-e053-3705fe0a095a
|
1
|
|
Polymeric nanoparticles for the drug delivery to the central nervous system, file e31e124a-9fc8-987f-e053-3705fe0a095a
|
1
|
|
Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors, file e31e124a-a11b-987f-e053-3705fe0a095a
|
1
|
|
PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid, file e31e124a-a168-987f-e053-3705fe0a095a
|
1
|
|
Privileged structures in medicinal chemistry, file e31e124a-a339-987f-e053-3705fe0a095a
|
1
|
|
Ghrelin receptor modulators and their therapeutic potential, file e31e124a-a33a-987f-e053-3705fe0a095a
|
1
|
|
Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?, file e31e124a-a516-987f-e053-3705fe0a095a
|
1
|
|
Ghrelin receptor modulators: a patent review (2011-2014), file e31e124a-a8dc-987f-e053-3705fe0a095a
|
1
|
|
Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution, file e31e124a-b153-987f-e053-3705fe0a095a
|
1
|
|
Discovery of new inhibitors of aldose reductase from molecular docking and database screening, file e31e124b-d8ad-987f-e053-3705fe0a095a
|
1
|
|
PABA-alginate complex as sunscreen agent, file e31e124b-e75f-987f-e053-3705fe0a095a
|
1
|
|
Solvent effects on the tautomerism of apigeninidin, file e31e124b-fd63-987f-e053-3705fe0a095a
|
1
|
|
Design, synthesis and biological evaluation of non-covalent AmpC Beta-Lactamases inhibitors, file e31e124d-8088-987f-e053-3705fe0a095a
|
1
|
|
Current and Future Chemotherapy for Chagas Disease, file e31e124f-91b5-987f-e053-3705fe0a095a
|
1
|
|
Current and Future Chemotherapy for Chagas Disease, file e31e124f-a820-987f-e053-3705fe0a095a
|
1
|
|
Current and Future Chemotherapy for Chagas Disease, file e31e124f-a821-987f-e053-3705fe0a095a
|
1
|
| Totale |
2.155 |
